{"title":"\"表皮生长因子受体(EGFR)突变非小细胞肺癌(NSCLC)患者接受奥希替尼前线治疗的局部巩固治疗,真实世界的经验\"","authors":"Benyounes A","doi":"10.26717/bjstr.2024.54.008541","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":505243,"journal":{"name":"Biomedical Journal of Scientific & Technical Research","volume":"57 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"\\\"Local Consolidation Therapy in Patients with EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib, A Real-World Experience\\\"\",\"authors\":\"Benyounes A\",\"doi\":\"10.26717/bjstr.2024.54.008541\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":505243,\"journal\":{\"name\":\"Biomedical Journal of Scientific & Technical Research\",\"volume\":\"57 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical Journal of Scientific & Technical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26717/bjstr.2024.54.008541\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Journal of Scientific & Technical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26717/bjstr.2024.54.008541","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
"Local Consolidation Therapy in Patients with EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib, A Real-World Experience"